tiprankstipranks
Trending News
More News >
CellSource Co., Ltd. (JP:4880)
:4880
Japanese Market
Advertisement

CellSource Co., Ltd. (4880) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4880

CellSource Co., Ltd.

(4880)

Rating:69Neutral
Price Target:
¥786.00
▲(12.29%Upside)
CellSource Co., Ltd. benefits from a strong financial position and positive cash flow generation, which are significant strengths. However, the stock's valuation is a major concern due to a negative P/E ratio, indicating potential profitability issues. Technical indicators suggest moderate bullish momentum, but overall, the stock presents mixed signals with more weight on financial stability.

CellSource Co., Ltd. (4880) vs. iShares MSCI Japan ETF (EWJ)

CellSource Co., Ltd. Business Overview & Revenue Model

Company DescriptionCellSource Co., Ltd. (4880) is a biotechnology company specializing in regenerative medicine and cell therapy solutions. The company focuses on the development and commercialization of cutting-edge treatments using stem cell technology, particularly for diseases and conditions that currently have limited therapeutic options. Their core services include the collection, processing, and storage of stem cells, as well as research and development of new regenerative therapies.
How the Company Makes MoneyCellSource Co., Ltd. generates revenue primarily through its stem cell processing and storage services, where clients pay for the collection, processing, and long-term storage of their stem cells for potential future medical use. Additionally, the company earns income through partnerships with healthcare institutions and research organizations for the development and commercialization of new regenerative medicine products. Revenue is also bolstered by licensing agreements for their proprietary technologies and solutions in the field of regenerative medicine.

CellSource Co., Ltd. Financial Statement Overview

Summary
CellSource Co., Ltd. has demonstrated stable revenue growth and effective cost management with a strong equity position. However, recent declines in net income and revenue growth pose challenges. Despite this, low leverage and solid cash flow generation provide stability.
Income Statement
75
Positive
CellSource Co., Ltd. has shown a consistent increase in total revenue over the years, demonstrating strong growth in the biotechnology sector. However, the latest year saw a slight decline in revenue. The gross profit margin is solid, indicating efficient cost management. The company has maintained a healthy net profit margin, although it has decreased recently due to lower net income. Overall, the income statement reflects a stable revenue base with some recent challenges in profitability.
Balance Sheet
80
Positive
The company's balance sheet reveals a robust financial position with a strong equity base and minimal debt, reflected in a low debt-to-equity ratio. The equity ratio is high, indicating a well-capitalized structure. Return on equity has decreased, correlating with the drop in net income, but remains positive. Overall, the balance sheet reflects financial stability and low leverage risk.
Cash Flow
78
Positive
CellSource has generated consistent operating cash flow, supporting its operations. Free cash flow has been positive, though its growth has been moderate recently. The operating cash flow to net income ratio is healthy, suggesting effective cash management. However, the recent decline in free cash flow growth highlights potential challenges in sustaining cash flow growth. Overall, the cash flow statement indicates solid cash generation with room for improvement.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.36B4.51B4.27B2.92B1.86B
Gross Profit2.42B3.18B3.06B2.07B1.26B
EBITDA449.53M1.31B1.64B1.06B476.46M
Net Income237.94M923.14M1.02B651.40M274.08M
Balance Sheet
Total Assets7.07B6.88B4.60B3.37B2.35B
Cash, Cash Equivalents and Short-Term Investments4.32B4.78B3.12B2.41B1.76B
Total Debt77.29M97.54M0.001.10M4.29M
Total Liabilities1.04B677.74M814.15M645.00M309.63M
Stockholders Equity6.04B6.20B3.79B2.72B2.04B
Cash Flow
Free Cash Flow52.04M487.69M748.44M836.74M297.50M
Operating Cash Flow591.72M846.69M847.60M898.19M330.23M
Investing Cash Flow-614.96M-624.08M-169.39M-256.12M-57.83M
Financing Cash Flow-437.24M1.45B14.42M9.35M152.65M

CellSource Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price700.00
Price Trends
50DMA
685.48
Positive
100DMA
696.20
Negative
200DMA
845.38
Negative
Market Momentum
MACD
3.58
Negative
RSI
51.11
Neutral
STOCH
53.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Neutral. The current price of 700 is above the 20-day moving average (MA) of 687.30, above the 50-day MA of 685.48, and below the 200-day MA of 845.38, indicating a neutral trend. The MACD of 3.58 indicates Negative momentum. The RSI at 51.11 is Neutral, neither overbought nor oversold. The STOCH value of 53.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4880.

CellSource Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
¥13.87B284.55
0.71%-13.57%-106.11%
67
Neutral
¥10.45B27.08
7.98%24.12%
55
Neutral
¥13.72B
256.62%81.71%
50
Neutral
AU$2.64B3.32-57.47%2.62%36.37%14.48%
49
Neutral
¥20.47B206.40
8.46%49.97%
47
Neutral
¥19.20B
-100.00%-1079.89%
46
Neutral
¥16.57B
-4.04%-0.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4880
CellSource Co., Ltd.
700.00
-853.43
-54.94%
JP:4599
StemRIM Inc.
309.00
-145.00
-31.94%
JP:4888
STELLA PHARMA CORPORATION
415.00
-19.00
-4.38%
JP:4978
ReproCELL Inc.
225.00
85.00
60.71%
JP:7096
StemCell Institute
1,020.00
-634.61
-38.35%
JP:7776
CellSeed Inc.
478.00
-37.00
-7.18%

CellSource Co., Ltd. Corporate Events

CellSource Announces Leadership Change to Drive Expansion
Jul 14, 2025

CellSource Co., Ltd. announced a leadership change, with Masayuki Yamakawa, a co-founder and medical doctor, taking over as Representative Director and CEO from Takashi Sawada. This transition aims to leverage the company’s robust management structure for significant expansion in regenerative medicine and self-funded healthcare, marking a shift to a more proactive management approach.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports Growth in June 2025 Contract Processing Orders
Jul 9, 2025

CellSource Co., Ltd. reported a notable increase in its daily average number of contract processing orders for June 2025, driven by a significant rise in blood-derived orders from its hybrid orthopedics segment. The company continues to strengthen its operations in self-funded orthopedics and hybrid orthopedics, with a focus on maintaining order volumes and expanding partnerships with key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Finalizes Stock Option Terms
Jun 30, 2025

CellSource Co., Ltd. has finalized the terms for its stock acquisition rights, initially resolved at a Board of Directors meeting on June 12, 2025. The finalized terms involve two employees receiving a total of 1,582 stock acquisition rights, with an exercise price set at 68,200 yen per right, equivalent to 682 yen per share.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen880.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Announces Six-Month Financial Results and Full-Year Forecast
Jun 12, 2025

CellSource Co., Ltd. reported its consolidated financial results for the six months ended April 30, 2025, under Japanese GAAP. The company achieved net sales of ¥1,820 million and a profit attributable to owners of ¥11 million. The equity-to-asset ratio stood at 85.1%, reflecting a strong financial position. The company has transitioned to consolidated accounting from the fiscal year ending October 31, 2025, which impacts the comparability of year-on-year changes. The financial forecast for the full year ending October 31, 2025, projects net sales of ¥4,501 million and a profit attributable to owners of ¥255 million.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Issues Stock Options to Employees to Boost Corporate Value
Jun 12, 2025

CellSource Co., Ltd. has announced the issuance of stock options to its employees, aimed at boosting corporate value and improving performance over the medium to long term. The issuance involves 1,582 stock acquisition rights, which, if fully exercised, will result in a maximum dilution of 0.8% of the total issued shares. The company believes this move will enhance shareholder value and considers the dilution impact to be within a reasonable range.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports Stable April 2025 KPI Results Amid Strategic Focus
May 13, 2025

CellSource Co., Ltd. reported its April 2025 KPI results, highlighting a stable daily average of processing orders at 58.5, consistent with March figures. Despite a slight decrease in orders for adipose-derived stem cell processing and non-orthopedic departments, the company maintained a steady number of blood-derived processing orders in its core orthopedic segment. The company noted a decrease in monthly orders for blood-derived products in both self-funded and hybrid orthopedics, with a 2.7% and 2.0% decline, respectively. However, they are focusing on strengthening their organizational structure and maintaining planned order volumes, while ongoing initiatives target key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025